GLP-1/glucagon dual receptor agonist ALT-801 is superior to semaglutide in improving NASH endpoints in a biopsy-confirmed DIO mouse model

被引：0
|
作者：
Nestor, John [1 ]
Rigbolt, Kristoffer [2 ]
Feigh, Michael [2 ]
Parkes, David [3 ]
Harris, M. Scott [1 ]
机构：
[1] Altimmune Inc, Gaithersburg, MD USA
[2] Gubra, Horsholm, Denmark
[3] DGP Sci, Del Mar, CA USA
来源：
JOURNAL OF HEPATOLOGY | 2020年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
FRI117
引用
收藏
页码：S456 / S456
页数：1
相关论文
共 45 条
  • [31] 2FA-Platform Generates Dual Fatty Acid-Conjugated GLP-1 Receptor Agonist TE-8105 with Enhanced Diabetes, Obesity, and NASH Efficacy Compared to Semaglutide
    Wong, Mun-Teng
    Lin, Pei-Hsuan
    Lin, Wei-Chen
    Peng, Chi-Jiun
    Wright, Jon D.
    Lee, Hui-Ju
    Chu, Hsing-Mao
    Lim, Carmay
    Chang, Tse Wen
    JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (06) : 6178 - 6192
  • [32] A Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson's Disease
    Zhang, Zijuan
    Shi, Ming
    Li, Zhengmin
    Ling, Yuan
    Zhai, Luke
    Yuan, Ye
    Ma, He
    Hao, Li
    Li, Zhonghua
    Zhang, Zhenqiang
    Holscher, Christian
    PARKINSONS DISEASE, 2023, 2023
  • [33] A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain
    Cao, Lijun
    Li, Dongfang
    Feng, Peng
    Li, Lin
    Xue, Guo-Fang
    Li, Guanglai
    Holscher, Christian
    NEUROREPORT, 2016, 27 (06) : 384 - 391
  • [34] THERAPEUTIC EFFECT OF A NOVEL LONG-ACTING GLUCAGON/GIP/GLP-1 TRIPLE AGONIST (HM15211) IN CDHFD-INDUCED MOUSE MODEL OF NASH AND FIBROSIS MICE
    Choi, Jaehyuk
    Lee, Seon Myeong
    Kim, Jung Kuk
    Jo, Hyo Sang
    Lee, Jong Suk
    Kwon, Hyunjoo
    Bae, Sung Min
    Kim, Dae Jin
    Lee, Sang Hyun
    Choi, In Young
    HEPATOLOGY, 2020, 72 : 1039 - 1039
  • [35] FXR/TGR5 Dual Agonist INT-767 Reduces NAS & Fibrosis & Improves Plasma & Hepatic Lipid Profiles in the AMLN Mouse Model of Diet-induced & Biopsy-confirmed NASH
    Roth, Jonathan
    Feigh, Michael
    Herrmann, Sibylle
    SWISS MEDICAL WEEKLY, 2017, 147 : 20S - 20S
  • [36] CT-859, A NOVEL FULLY BIASED UNIMOLECULAR DUAL GLP-1 AND GIP RECEPTOR MODULATOR RESOLVES NASH AND FIBROSIS, DECREASES TUMORS, AND IMPROVES SURVIVAL IN A MOUSE NASH MODEL
    Enquist, Johan
    Fucini, Ray
    Sawayama, Andrew
    Krishnan, Shyam
    Bone, Derek
    Tracy, Ted
    Lloyd, David
    Iwig, Jeff
    Erlanson, Dan
    Chakravarthy, Manu V.
    Hansen, Stig
    HEPATOLOGY, 2021, 74 : 1134A - 1135A
  • [37] Multiple dose-ranging study of the novel glucagon/GLP-1 receptor dual agonist BI 456906 vs placebo and open-label weekly semaglutide reference control in type 2 diabetes
    Rosenstock, J.
    Blueher, M.
    Schmid, B.
    Hoefler, J.
    Hennige, A.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S314 - S315
  • [38] The GLP-1/GIP dual-receptor agonist DA5-CH inhibits the NF-κB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01
    Lv, MiaoJun
    Xue, GuoFang
    Cheng, HuiFeng
    Meng, PengFei
    Lian, Xia
    Holscher, Christian
    Li, DongFang
    BRAIN AND BEHAVIOR, 2021, 11 (08):
  • [39] Combination therapy of TERN-501, a selective agonist of thyroid hormone receptor (THR) beta with TERN-101, a farnesoid X receptor (FXR) agonist improves non-alcoholic steatohepatitis (NASH) in a GAN diet-induced and biopsy-confirmed mouse model
    Jones, Christopher
    Nielsen, Malte H.
    Oro, Denise
    Feigh, Michael
    Teng, Xiao
    Lie, Anthony
    Ho, Gideon
    Jasper, Jeffrey
    JOURNAL OF HEPATOLOGY, 2023, 78 : S763 - S764
  • [40] Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
    Matthias Blüher
    Julio Rosenstock
    Josef Hoefler
    Raymond Manuel
    Anita M. Hennige
    Diabetologia, 2024, 67 : 470 - 482
12345